Aegerion Pharmaceuticals Reserves Shares for Inducement Stock Options

Aegerion Pharmaceuticals Reserves Shares for Inducement Stock Options

CAMBRIDGE, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, today announced that, in support of Aegerion's
build of its U.S. commercial organization and international expansion, the
Compensation Committee of the Company's Board of Directors has approved the
reservation of 1,000,000 shares of common stock to be used exclusively for the
grant of non-qualified stock options to individuals who were not previously an
employee or non-employee director of Aegerion (or following a bona fide period
of non-employment), as an inducement new hire stock option award material to
an individual's entry into employment within the meaning of Rule 5635(c)(4) of
the NASDAQ Listing Rules (Inducement Stock Options).  

On December 3, 2012, Aegerion granted stock options to purchase an aggregate
of 218,600 shares of common stock to 23 new employees under the inducement
grant program. Each stock option has an exercise price per share equal to
$21.55, the closing price of Aegerion's common stock on the grant date, and
vests in equal monthly installments over four years.Each stock option has a
ten year term and will be subject to the terms and conditions of a stock
option agreement covering the grant. 

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on
the development and commercialization of novel, life-altering therapeutics to
treat debilitating and often fatal rare diseases. The company's lead drug
candidate, lomitapide, is in late-stage development for the treatment of
homozygous familial hypercholesterolemia (HoFH), a rare life-threatening
disease characterized by severely elevated cholesterol levels. 

Aegerion is motivated by its commitment to patients first, as well as its core
values of integrity, innovation, responsibility to healthcare providers and
development of employees, with a constant focus on scientific and clinical
excellence. For more information, visit www.aegerion.com.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Michael Lawless
         Vice President, Investor Relations
         (857) 242-5028
 
Press spacebar to pause and continue. Press esc to stop.